Verisante Technology's CEO Thomas Braun Interviewed by The Life Sciences Report

SAN FRANCISCO, CA--(Marketwired - Apr 21, 2014) - Early detection of cancer has a profound impact on the effectiveness of medical/surgical treatments, as well as on the long-term prognoses of patients. Consequently, new technologies are evolving with the ability to detect cancers in their earliest and most treatable stages. In this interview with The Life Sciences Report, Thomas Braun, president and CEO of Verisante Technology Inc. (TSX-VENTURE: VRS) (OTCQX: VRSEF), describes his company's Aura and Core devices, and their utility in early cancer detection.

The Life Sciences Report: Verisante is focused on the early detection of skin cancer. Can you talk about the market size in this area?

Thomas Braun: The most common cancers are skin cancers, with 1 in 5 people expected to get skin cancer in their lifetime. Tens of millions of people will be diagnosed. However, many more people will be screened to determine whether they actually have skin cancer. It's important to note that 95-97% of skin cancers are not melanoma. Therefore, it is critical to be able to detect all types of skin cancer, not just melanoma.

TLSR: Can you tell me about the challenges associated with the early detection of skin cancer?

TB: Skin cancer is extremely complicated. It's actually more complicated than internal cancers because there are about 100 different types of skin lesions, most of them benign. In addition, you have about 10 different types of skin on your body...

Continue reading this interview with Thomas Braun: Novel Tools for Early Cancer Detection: Verisante Technology Inc.

About Streetwise Reports - The Life Sciences Report

Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. Our exclusive interviews with leading industry experts and analysts provide a clear picture of the causes of macro-economic shifts and the strategies that will help you capitalize on these developing trends.

DISCLOSURE: Verisante Technology Inc. paid The Life Sciences Report to conduct, produce and distribute the interview. Verisante Technology Inc. had final approval of the content and is wholly responsible for the validity of the statements. Opinions expressed are the opinions of Verisante Technology Inc. and not Streetwise Reports or The Life Sciences Report or its officers.

Verisante Technology (CE) (USOTC:VRSEF)
Historical Stock Chart
From Mar 2024 to Apr 2024